Cluster Headache Syndrome Market Report 2024

The cluster headache syndrome market size has grown strongly in recent years. It will grow from $0.75 billion in 2023 to $0.8 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The growth during the historic period can be attributed to an increase in public health initiatives, advancements in research and development for headache treatments, heightened awareness of neurological disorders, expansion of multinational clinical trials, and greater availability of supportive therapies.

The cluster headache syndrome market size is expected to see strong growth in the next few years. It will grow to $1.04 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth during the forecast period can be attributed to the increasing prevalence of neurological disorders, growing investments in the development of new drugs, higher healthcare spending, a rising number of depression cases, and an increase in drug approvals. Major trends for this period include technological advancements, telemedicine, personalized medicine, neuromodulation techniques, and targeted drug therapies.

The increasing prevalence of neurological disorders is anticipated to drive the growth of the cluster headache syndrome market. Neurological disorders encompass a range of conditions affecting the nervous system, including the brain, spinal cord, and nerves throughout the body. The rise in neurological disorders is influenced by factors such as the growing prevalence of risk factors such as diabetes, improved diagnostic capabilities, neurological complications from other conditions, and socioeconomic disparities. Treatments for neurological disorders can help manage cluster headache syndrome, as some of these conditions overlap with or impact headache pathways. Addressing the symptoms and underlying factors of cluster headaches can effectively reduce their frequency, severity, and impact. For instance, in April 2022, the European Brain Council, a Belgium-based non-profit organization, reported that 10.5 million Europeans were affected by dementia (a neurological disorder), with this number expected to rise to 18.7 million by 2050. Therefore, the growing prevalence of neurological disorders is driving the cluster headache syndrome market.

Leading companies in the cluster headache syndrome market are focusing on developing advanced technologies, such as implantable neurostimulation systems, to offer more effective treatment options. Implantable neurostimulation technology involves surgically implanted devices that deliver electrical impulses to specific areas of the nervous system. For example, in May 2021, Unity HA, a US-based medical device company, launched the Pulsante SPG Microstimulator System for treating acute pain associated with chronic cluster headaches. Approved by the Food and Drug Administration (FDA), this innovative implantable device features advanced neurostimulation techniques specifically designed to target the neural pathways related to cluster headaches, providing a more precise and effective pain management solution. The device is minimally invasive, with a small, implantable unit that can be discreetly placed and adjusted as needed.

In October 2022, Emergex Vaccines Holding Limited, a UK-based biotechnology company, acquired the assets of Zosano Pharma Corporation, including intellectual property, license agreements, and manufacturing equipment, for an undisclosed amount. This acquisition enables Emergex to utilize Zosano's microneedle patch technology and manufacturing capabilities. Zosano Pharma Corporation is a US-based clinical-stage biopharmaceutical company specializing in developing treatments for cluster headache syndrome.

Major companies operating in the cluster headache syndrome market are Pfizer Inc., Bayer AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Hikma Pharmaceuticals, Amneal Pharmaceuticals, Grünenthal GmbH, Mallinckrodt Pharmaceuticals, Upsher-Smith Laboratories, Zogenix Inc., Neurelis Inc., ElectroCore Medical LLC, Ceruvia Lifesciences, TrioxBio Inc., Winston Pharmaceuticals Inc., Zosano Pharma Corporation, Autonomic Technologies Inc., H. Lundbeck A/S.

North America was the largest region in the cluster headache syndrome market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cluster headache syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cluster headache syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cluster headache syndrome is a condition marked by severe, recurrent headaches that occur in clusters or episodes. These headaches are typically one-sided and extremely painful, often described as sharp, burning, or piercing sensations. They usually manifest around the eye or temple area and last between 15 minutes and three hours.

The main types of cluster headache syndrome are episodic and chronic. Episodic cluster headache features relatively long, pain-free remissions between headache episodes and is the more common type, affecting about 90% of those with the condition. Various medications used to treat cluster headaches include calcium channel blockers, corticosteroids, sumatriptan, lithium carbonate, ergots, melatonin, anti-seizure drugs, and local anesthetics. Diagnosis may involve neurological examination, magnetic resonance imaging (MRI), and computed tomography (CT) scans. Treatments can be administered orally, topically, intravenously, and through other methods, and are available through channels such as hospital pharmacies, retail pharmacies, online stores, and more.

The cluster headache syndromes market research report is one of a series of new reports that provides cluster headache syndromes market statistics, including cluster headache syndromes industry global market size, regional shares, competitors with a cluster headache syndromes market share, detailed cluster headache syndromes market segments, market trends, and opportunities, and any further data you may need to thrive in the cluster headache syndromes industry. This cluster headache syndromes research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cluster headache syndrome market consists of revenues earned by entities by providing services such as clinical services, specialized consultations, patient education programs, and support services. and related medical devices, microneedle patch technology, and diagnostic tools. The market value includes the value of related goods sold by the service provider or included within the service offering. The cluster headache syndrome market also includes sales of abortive medication, fast-acting analgesics, calcium channel blockers, corticosteroids, and anticonvulsants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.